For the first time, China biotechs made more money out-licensing assets in 2023 than in-licensing them.
Allorion scores second deal of the week in $1B pact with Avenzo
AstraZeneca adds another China-originated cancer drug to pipeline
Allorion Therapeutics has raised another $50 million in a Series B financing round to get Phase I/II clinical trials in both China and the US off the ground, the oncology and autoimmune disease-focused biotech announced Thursday.